Trial Profile
TCR-a/b+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Haematopoietic stem cell therapy (Primary) ; Zoledronic acid (Primary) ; Antithymocyte globulin; Fludarabine; Melphalan; Mycophenolate mofetil; Tacrolimus; Tacrolimus; Thiotepa
- Indications Acute myeloid leukaemia; Bone metastases; Cancer metastases; Ewing's sarcoma; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Myeloproliferative disorders; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- 14 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 14 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 09 May 2023 Planned End Date changed from 1 Nov 2025 to 1 Dec 2023.